Xtant Medical Holdings, Inc.
Xtant Medical Holdings, Inc. XTNT Peers
See (XTNT) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| XTNT | $0.74 | +1.42% | 102.65M | -8.19 | -$0.09 | N/A |
| ABT | $131.24 | -0.20% | 228.34B | 17.04 | $7.70 | +1.73% |
| BSX-PA | $122.18 | +2.37% | 175.45B | 230.53 | $0.53 | N/A |
| BSX | $104.46 | -0.04% | 154.54B | 76.25 | $1.37 | N/A |
| SYK | $376.69 | -0.42% | 143.96B | 50.83 | $7.41 | +0.87% |
| MDT | $80.69 | -0.27% | 103.49B | 22.35 | $3.61 | +3.47% |
| EW | $74.99 | +0.26% | 43.99B | 30.99 | $2.42 | N/A |
| DXCM | $84.51 | -0.38% | 33.14B | 63.54 | $1.33 | N/A |
| STE | $242.97 | -0.34% | 23.87B | 39.38 | $6.17 | +0.92% |
| PODD | $321.36 | +0.11% | 22.62B | 57.90 | $5.55 | N/A |
Stock Comparison
XTNT vs ABT Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, ABT has a market cap of 228.34B. Regarding current trading prices, XTNT is priced at $0.74, while ABT trades at $131.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas ABT's P/E ratio is 17.04. In terms of profitability, XTNT's ROE is -0.27%, compared to ABT's ROE of +0.24%. Regarding short-term risk, XTNT is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs BSX-PA Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, BSX-PA has a market cap of 175.45B. Regarding current trading prices, XTNT is priced at $0.74, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, XTNT's ROE is -0.27%, compared to BSX-PA's ROE of +0.10%. Regarding short-term risk, XTNT is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs BSX Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, BSX has a market cap of 154.54B. Regarding current trading prices, XTNT is priced at $0.74, while BSX trades at $104.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas BSX's P/E ratio is 76.25. In terms of profitability, XTNT's ROE is -0.27%, compared to BSX's ROE of +0.10%. Regarding short-term risk, XTNT is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs SYK Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, SYK has a market cap of 143.96B. Regarding current trading prices, XTNT is priced at $0.74, while SYK trades at $376.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas SYK's P/E ratio is 50.83. In terms of profitability, XTNT's ROE is -0.27%, compared to SYK's ROE of +0.11%. Regarding short-term risk, XTNT is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs MDT Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, MDT has a market cap of 103.49B. Regarding current trading prices, XTNT is priced at $0.74, while MDT trades at $80.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas MDT's P/E ratio is 22.35. In terms of profitability, XTNT's ROE is -0.27%, compared to MDT's ROE of +0.09%. Regarding short-term risk, XTNT is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs EW Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, EW has a market cap of 43.99B. Regarding current trading prices, XTNT is priced at $0.74, while EW trades at $74.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas EW's P/E ratio is 30.99. In terms of profitability, XTNT's ROE is -0.27%, compared to EW's ROE of +0.49%. Regarding short-term risk, XTNT is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs DXCM Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, DXCM has a market cap of 33.14B. Regarding current trading prices, XTNT is priced at $0.74, while DXCM trades at $84.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas DXCM's P/E ratio is 63.54. In terms of profitability, XTNT's ROE is -0.27%, compared to DXCM's ROE of +0.24%. Regarding short-term risk, XTNT is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs STE Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, STE has a market cap of 23.87B. Regarding current trading prices, XTNT is priced at $0.74, while STE trades at $242.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas STE's P/E ratio is 39.38. In terms of profitability, XTNT's ROE is -0.27%, compared to STE's ROE of +0.09%. Regarding short-term risk, XTNT is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs PODD Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, PODD has a market cap of 22.62B. Regarding current trading prices, XTNT is priced at $0.74, while PODD trades at $321.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas PODD's P/E ratio is 57.90. In terms of profitability, XTNT's ROE is -0.27%, compared to PODD's ROE of +0.35%. Regarding short-term risk, XTNT is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs PHG Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, PHG has a market cap of 20.86B. Regarding current trading prices, XTNT is priced at $0.74, while PHG trades at $22.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas PHG's P/E ratio is 77.76. In terms of profitability, XTNT's ROE is -0.27%, compared to PHG's ROE of +0.03%. Regarding short-term risk, XTNT is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs ZBH Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, ZBH has a market cap of 18.33B. Regarding current trading prices, XTNT is priced at $0.74, while ZBH trades at $92.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas ZBH's P/E ratio is 20.59. In terms of profitability, XTNT's ROE is -0.27%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, XTNT is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs ABMD Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, ABMD has a market cap of 17.18B. Regarding current trading prices, XTNT is priced at $0.74, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas ABMD's P/E ratio is 65.36. In terms of profitability, XTNT's ROE is -0.27%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, XTNT is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs SWAV Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, SWAV has a market cap of 12.57B. Regarding current trading prices, XTNT is priced at $0.74, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas SWAV's P/E ratio is 78.76. In terms of profitability, XTNT's ROE is -0.27%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, XTNT is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs SNN Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, SNN has a market cap of 12.53B. Regarding current trading prices, XTNT is priced at $0.74, while SNN trades at $28.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas SNN's P/E ratio is 30.46. In terms of profitability, XTNT's ROE is -0.27%, compared to SNN's ROE of +0.08%. Regarding short-term risk, XTNT is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs ALGN Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, ALGN has a market cap of 12.38B. Regarding current trading prices, XTNT is priced at $0.74, while ALGN trades at $170.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas ALGN's P/E ratio is 31.05. In terms of profitability, XTNT's ROE is -0.27%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, XTNT is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs PEN Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, PEN has a market cap of 10.41B. Regarding current trading prices, XTNT is priced at $0.74, while PEN trades at $268.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas PEN's P/E ratio is 248.81. In terms of profitability, XTNT's ROE is -0.27%, compared to PEN's ROE of +0.04%. Regarding short-term risk, XTNT is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs GMED Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, GMED has a market cap of 7.98B. Regarding current trading prices, XTNT is priced at $0.74, while GMED trades at $58.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas GMED's P/E ratio is 43.99. In terms of profitability, XTNT's ROE is -0.27%, compared to GMED's ROE of +0.05%. Regarding short-term risk, XTNT is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs BIO-B Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, BIO-B has a market cap of 6.76B. Regarding current trading prices, XTNT is priced at $0.74, while BIO-B trades at $250.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas BIO-B's P/E ratio is -3.27. In terms of profitability, XTNT's ROE is -0.27%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, XTNT is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs BIO Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, BIO has a market cap of 6.10B. Regarding current trading prices, XTNT is priced at $0.74, while BIO trades at $223.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas BIO's P/E ratio is -2.92. In terms of profitability, XTNT's ROE is -0.27%, compared to BIO's ROE of -0.32%. Regarding short-term risk, XTNT is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs GKOS Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, GKOS has a market cap of 5.49B. Regarding current trading prices, XTNT is priced at $0.74, while GKOS trades at $96.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas GKOS's P/E ratio is -42.29. In terms of profitability, XTNT's ROE is -0.27%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, XTNT is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs BRKR Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, BRKR has a market cap of 5.38B. Regarding current trading prices, XTNT is priced at $0.74, while BRKR trades at $35.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas BRKR's P/E ratio is 68.27. In terms of profitability, XTNT's ROE is -0.27%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, XTNT is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs NARI Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, NARI has a market cap of 4.68B. Regarding current trading prices, XTNT is priced at $0.74, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas NARI's P/E ratio is -59.24. In terms of profitability, XTNT's ROE is -0.27%, compared to NARI's ROE of -0.18%. Regarding short-term risk, XTNT is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs IRTC Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, IRTC has a market cap of 4.56B. Regarding current trading prices, XTNT is priced at $0.74, while IRTC trades at $142.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas IRTC's P/E ratio is -45.59. In terms of profitability, XTNT's ROE is -0.27%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, XTNT is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs INSP Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, INSP has a market cap of 4.22B. Regarding current trading prices, XTNT is priced at $0.74, while INSP trades at $143.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas INSP's P/E ratio is 65.35. In terms of profitability, XTNT's ROE is -0.27%, compared to INSP's ROE of +0.10%. Regarding short-term risk, XTNT is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs TMDX Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, TMDX has a market cap of 4.20B. Regarding current trading prices, XTNT is priced at $0.74, while TMDX trades at $124.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas TMDX's P/E ratio is 87.50. In terms of profitability, XTNT's ROE is -0.27%, compared to TMDX's ROE of +0.22%. Regarding short-term risk, XTNT is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs ITGR Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, ITGR has a market cap of 4.13B. Regarding current trading prices, XTNT is priced at $0.74, while ITGR trades at $118.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas ITGR's P/E ratio is 55.04. In terms of profitability, XTNT's ROE is -0.27%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, XTNT is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs AXNX Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, AXNX has a market cap of 3.63B. Regarding current trading prices, XTNT is priced at $0.74, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas AXNX's P/E ratio is -709.80. In terms of profitability, XTNT's ROE is -0.27%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, XTNT is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs PRCT Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, PRCT has a market cap of 3.17B. Regarding current trading prices, XTNT is priced at $0.74, while PRCT trades at $57.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas PRCT's P/E ratio is -33.95. In terms of profitability, XTNT's ROE is -0.27%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, XTNT is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs LIVN Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, LIVN has a market cap of 2.28B. Regarding current trading prices, XTNT is priced at $0.74, while LIVN trades at $41.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas LIVN's P/E ratio is -10.29. In terms of profitability, XTNT's ROE is -0.27%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, XTNT is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs NUVA Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, NUVA has a market cap of 2.08B. Regarding current trading prices, XTNT is priced at $0.74, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas NUVA's P/E ratio is 75.00. In terms of profitability, XTNT's ROE is -0.27%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, XTNT is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs ATEC Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, ATEC has a market cap of 1.82B. Regarding current trading prices, XTNT is priced at $0.74, while ATEC trades at $12.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas ATEC's P/E ratio is -10.92. In terms of profitability, XTNT's ROE is -0.27%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, XTNT is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs UFPT Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, UFPT has a market cap of 1.81B. Regarding current trading prices, XTNT is priced at $0.74, while UFPT trades at $234.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas UFPT's P/E ratio is 28.73. In terms of profitability, XTNT's ROE is -0.27%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, XTNT is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs CNMD Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, CNMD has a market cap of 1.71B. Regarding current trading prices, XTNT is priced at $0.74, while CNMD trades at $55.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas CNMD's P/E ratio is 14.54. In terms of profitability, XTNT's ROE is -0.27%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, XTNT is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs TNDM Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, TNDM has a market cap of 1.38B. Regarding current trading prices, XTNT is priced at $0.74, while TNDM trades at $20.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas TNDM's P/E ratio is -7.43. In terms of profitability, XTNT's ROE is -0.27%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, XTNT is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs HSKA Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, HSKA has a market cap of 1.31B. Regarding current trading prices, XTNT is priced at $0.74, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas HSKA's P/E ratio is -62.49. In terms of profitability, XTNT's ROE is -0.27%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, XTNT is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs AORT Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, AORT has a market cap of 1.22B. Regarding current trading prices, XTNT is priced at $0.74, while AORT trades at $28.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas AORT's P/E ratio is -56.12. In terms of profitability, XTNT's ROE is -0.27%, compared to AORT's ROE of -0.07%. Regarding short-term risk, XTNT is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs AHCO Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, AHCO has a market cap of 1.18B. Regarding current trading prices, XTNT is priced at $0.74, while AHCO trades at $8.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas AHCO's P/E ratio is 15.14. In terms of profitability, XTNT's ROE is -0.27%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, XTNT is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs SILK Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, SILK has a market cap of 1.12B. Regarding current trading prices, XTNT is priced at $0.74, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas SILK's P/E ratio is -18.96. In terms of profitability, XTNT's ROE is -0.27%, compared to SILK's ROE of -0.37%. Regarding short-term risk, XTNT is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs FNA Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, FNA has a market cap of 1.10B. Regarding current trading prices, XTNT is priced at $0.74, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas FNA's P/E ratio is -19.83. In terms of profitability, XTNT's ROE is -0.27%, compared to FNA's ROE of -0.36%. Regarding short-term risk, XTNT is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs ESTA Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, ESTA has a market cap of 1.06B. Regarding current trading prices, XTNT is priced at $0.74, while ESTA trades at $36.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas ESTA's P/E ratio is -11.74. In terms of profitability, XTNT's ROE is -0.27%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, XTNT is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs INMD Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, INMD has a market cap of 989.82M. Regarding current trading prices, XTNT is priced at $0.74, while INMD trades at $14.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas INMD's P/E ratio is 6.38. In terms of profitability, XTNT's ROE is -0.27%, compared to INMD's ROE of +0.25%. Regarding short-term risk, XTNT is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs IART Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, IART has a market cap of 955.86M. Regarding current trading prices, XTNT is priced at $0.74, while IART trades at $12.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas IART's P/E ratio is -32.37. In terms of profitability, XTNT's ROE is -0.27%, compared to IART's ROE of -0.03%. Regarding short-term risk, XTNT is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs CSII Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, CSII has a market cap of 843.96M. Regarding current trading prices, XTNT is priced at $0.74, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas CSII's P/E ratio is -20.83. In terms of profitability, XTNT's ROE is -0.27%, compared to CSII's ROE of -0.14%. Regarding short-term risk, XTNT is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs SIBN Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, SIBN has a market cap of 783.25M. Regarding current trading prices, XTNT is priced at $0.74, while SIBN trades at $18.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas SIBN's P/E ratio is -29.17. In terms of profitability, XTNT's ROE is -0.27%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, XTNT is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs CRY Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, CRY has a market cap of 725.15M. Regarding current trading prices, XTNT is priced at $0.74, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas CRY's P/E ratio is 425.71. In terms of profitability, XTNT's ROE is -0.27%, compared to CRY's ROE of -0.07%. Regarding short-term risk, XTNT is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs IRMD Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, IRMD has a market cap of 647.07M. Regarding current trading prices, XTNT is priced at $0.74, while IRMD trades at $50.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas IRMD's P/E ratio is 32.83. In terms of profitability, XTNT's ROE is -0.27%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, XTNT is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs RXST Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, RXST has a market cap of 637.19M. Regarding current trading prices, XTNT is priced at $0.74, while RXST trades at $15.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas RXST's P/E ratio is -23.76. In terms of profitability, XTNT's ROE is -0.27%, compared to RXST's ROE of -0.10%. Regarding short-term risk, XTNT is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs CBLL Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, CBLL has a market cap of 599.25M. Regarding current trading prices, XTNT is priced at $0.74, while CBLL trades at $16.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas CBLL's P/E ratio is -13.26. In terms of profitability, XTNT's ROE is -0.27%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, XTNT is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs NPCE Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, NPCE has a market cap of 579.88M. Regarding current trading prices, XTNT is priced at $0.74, while NPCE trades at $17.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas NPCE's P/E ratio is -21.56. In terms of profitability, XTNT's ROE is -0.27%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, XTNT is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.
XTNT vs APEN Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, APEN has a market cap of 579.72M. Regarding current trading prices, XTNT is priced at $0.74, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas APEN's P/E ratio is -9.43. In terms of profitability, XTNT's ROE is -0.27%, compared to APEN's ROE of -0.85%. Regarding short-term risk, XTNT is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs AVNS Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, AVNS has a market cap of 568.34M. Regarding current trading prices, XTNT is priced at $0.74, while AVNS trades at $12.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas AVNS's P/E ratio is -1.49. In terms of profitability, XTNT's ROE is -0.27%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, XTNT is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs BFLY Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, BFLY has a market cap of 537.85M. Regarding current trading prices, XTNT is priced at $0.74, while BFLY trades at $2.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas BFLY's P/E ratio is -7.25. In terms of profitability, XTNT's ROE is -0.27%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, XTNT is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs BFLY-WT Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, BFLY-WT has a market cap of 525.29M. Regarding current trading prices, XTNT is priced at $0.74, while BFLY-WT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, XTNT's ROE is -0.27%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, XTNT is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.
XTNT vs KIDS Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, KIDS has a market cap of 515.94M. Regarding current trading prices, XTNT is priced at $0.74, while KIDS trades at $20.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas KIDS's P/E ratio is -11.84. In terms of profitability, XTNT's ROE is -0.27%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, XTNT is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs AXGN Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, AXGN has a market cap of 504.17M. Regarding current trading prices, XTNT is priced at $0.74, while AXGN trades at $11.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas AXGN's P/E ratio is -69.19. In terms of profitability, XTNT's ROE is -0.27%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, XTNT is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs SMLR Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, SMLR has a market cap of 494.24M. Regarding current trading prices, XTNT is priced at $0.74, while SMLR trades at $44.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas SMLR's P/E ratio is -18.54. In terms of profitability, XTNT's ROE is -0.27%, compared to SMLR's ROE of -0.21%. Regarding short-term risk, XTNT is less volatile compared to SMLR. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.
XTNT vs OFIX Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, OFIX has a market cap of 434.91M. Regarding current trading prices, XTNT is priced at $0.74, while OFIX trades at $11.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas OFIX's P/E ratio is -3.00. In terms of profitability, XTNT's ROE is -0.27%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, XTNT is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs BVS Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, BVS has a market cap of 433.32M. Regarding current trading prices, XTNT is priced at $0.74, while BVS trades at $6.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas BVS's P/E ratio is -13.60. In terms of profitability, XTNT's ROE is -0.27%, compared to BVS's ROE of -0.21%. Regarding short-term risk, XTNT is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs SRDX Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, SRDX has a market cap of 410.39M. Regarding current trading prices, XTNT is priced at $0.74, while SRDX trades at $28.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas SRDX's P/E ratio is -20.50. In terms of profitability, XTNT's ROE is -0.27%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, XTNT is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs SENS Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, SENS has a market cap of 384.46M. Regarding current trading prices, XTNT is priced at $0.74, while SENS trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas SENS's P/E ratio is -4.63. In terms of profitability, XTNT's ROE is -0.27%, compared to SENS's ROE of -7.46%. Regarding short-term risk, XTNT is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs TMCI Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, TMCI has a market cap of 369.88M. Regarding current trading prices, XTNT is priced at $0.74, while TMCI trades at $5.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas TMCI's P/E ratio is -6.92. In terms of profitability, XTNT's ROE is -0.27%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, XTNT is more volatile compared to TMCI. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs CLPT Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, CLPT has a market cap of 336.07M. Regarding current trading prices, XTNT is priced at $0.74, while CLPT trades at $11.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas CLPT's P/E ratio is -15.64. In terms of profitability, XTNT's ROE is -0.27%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, XTNT is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs NNOX Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, NNOX has a market cap of 327.10M. Regarding current trading prices, XTNT is priced at $0.74, while NNOX trades at $5.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas NNOX's P/E ratio is -5.64. In terms of profitability, XTNT's ROE is -0.27%, compared to NNOX's ROE of -0.30%. Regarding short-term risk, XTNT is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs OM Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, OM has a market cap of 318.12M. Regarding current trading prices, XTNT is priced at $0.74, while OM trades at $17.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas OM's P/E ratio is -0.62. In terms of profitability, XTNT's ROE is -0.27%, compared to OM's ROE of -1.45%. Regarding short-term risk, XTNT is more volatile compared to OM. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs VREX Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, VREX has a market cap of 312.08M. Regarding current trading prices, XTNT is priced at $0.74, while VREX trades at $7.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas VREX's P/E ratio is -7.30. In terms of profitability, XTNT's ROE is -0.27%, compared to VREX's ROE of -0.08%. Regarding short-term risk, XTNT is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs CTKB Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, CTKB has a market cap of 306.51M. Regarding current trading prices, XTNT is priced at $0.74, while CTKB trades at $2.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas CTKB's P/E ratio is -26.89. In terms of profitability, XTNT's ROE is -0.27%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, XTNT is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs PACB Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, PACB has a market cap of 276.62M. Regarding current trading prices, XTNT is priced at $0.74, while PACB trades at $0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas PACB's P/E ratio is -0.34. In terms of profitability, XTNT's ROE is -0.27%, compared to PACB's ROE of -1.70%. Regarding short-term risk, XTNT is more volatile compared to PACB. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs VMD Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, VMD has a market cap of 253.74M. Regarding current trading prices, XTNT is priced at $0.74, while VMD trades at $6.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas VMD's P/E ratio is 21.40. In terms of profitability, XTNT's ROE is -0.27%, compared to VMD's ROE of +0.10%. Regarding short-term risk, XTNT is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs CERS Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, CERS has a market cap of 238.95M. Regarding current trading prices, XTNT is priced at $0.74, while CERS trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas CERS's P/E ratio is -12.50. In terms of profitability, XTNT's ROE is -0.27%, compared to CERS's ROE of -0.35%. Regarding short-term risk, XTNT is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs MXCT Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, MXCT has a market cap of 232.84M. Regarding current trading prices, XTNT is priced at $0.74, while MXCT trades at $2.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas MXCT's P/E ratio is -5.47. In terms of profitability, XTNT's ROE is -0.27%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, XTNT is more volatile compared to MXCT. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs ZIMV Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, ZIMV has a market cap of 231.19M. Regarding current trading prices, XTNT is priced at $0.74, while ZIMV trades at $8.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas ZIMV's P/E ratio is -9.20. In terms of profitability, XTNT's ROE is -0.27%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, XTNT is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs NVRO Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, NVRO has a market cap of 224.09M. Regarding current trading prices, XTNT is priced at $0.74, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas NVRO's P/E ratio is -1.91. In terms of profitability, XTNT's ROE is -0.27%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, XTNT is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs TCMD Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, TCMD has a market cap of 219.00M. Regarding current trading prices, XTNT is priced at $0.74, while TCMD trades at $9.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas TCMD's P/E ratio is 14.27. In terms of profitability, XTNT's ROE is -0.27%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, XTNT is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs TLSI Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, TLSI has a market cap of 210.38M. Regarding current trading prices, XTNT is priced at $0.74, while TLSI trades at $5.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas TLSI's P/E ratio is -5.05. In terms of profitability, XTNT's ROE is -0.27%, compared to TLSI's ROE of +1.07%. Regarding short-term risk, XTNT is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.
XTNT vs EYES Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, EYES has a market cap of 210.05M. Regarding current trading prices, XTNT is priced at $0.74, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas EYES's P/E ratio is N/A. In terms of profitability, XTNT's ROE is -0.27%, compared to EYES's ROE of -0.26%. Regarding short-term risk, XTNT is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs BWAY Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, BWAY has a market cap of 202.59M. Regarding current trading prices, XTNT is priced at $0.74, while BWAY trades at $10.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas BWAY's P/E ratio is 48.77. In terms of profitability, XTNT's ROE is -0.27%, compared to BWAY's ROE of +0.06%. Regarding short-term risk, XTNT is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs QTRX Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, QTRX has a market cap of 188.32M. Regarding current trading prices, XTNT is priced at $0.74, while QTRX trades at $4.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas QTRX's P/E ratio is -3.91. In terms of profitability, XTNT's ROE is -0.27%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, XTNT is more volatile compared to QTRX. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs CATX Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, CATX has a market cap of 178.15M. Regarding current trading prices, XTNT is priced at $0.74, while CATX trades at $2.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas CATX's P/E ratio is -1.95. In terms of profitability, XTNT's ROE is -0.27%, compared to CATX's ROE of -0.27%. Regarding short-term risk, XTNT is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.
XTNT vs BDMD Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, BDMD has a market cap of 176.14M. Regarding current trading prices, XTNT is priced at $0.74, while BDMD trades at $4.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas BDMD's P/E ratio is 10.06. In terms of profitability, XTNT's ROE is -0.27%, compared to BDMD's ROE of +0.12%. Regarding short-term risk, XTNT is more volatile compared to BDMD. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs INGN Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, INGN has a market cap of 175.57M. Regarding current trading prices, XTNT is priced at $0.74, while INGN trades at $6.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas INGN's P/E ratio is -5.68. In terms of profitability, XTNT's ROE is -0.27%, compared to INGN's ROE of -0.15%. Regarding short-term risk, XTNT is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs CVRX Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, CVRX has a market cap of 173.90M. Regarding current trading prices, XTNT is priced at $0.74, while CVRX trades at $6.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas CVRX's P/E ratio is -3.12. In terms of profitability, XTNT's ROE is -0.27%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, XTNT is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs MASS Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, MASS has a market cap of 172.13M. Regarding current trading prices, XTNT is priced at $0.74, while MASS trades at $4.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas MASS's P/E ratio is -2.16. In terms of profitability, XTNT's ROE is -0.27%, compared to MASS's ROE of -0.13%. Regarding short-term risk, XTNT is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs LUCD Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, LUCD has a market cap of 172.02M. Regarding current trading prices, XTNT is priced at $0.74, while LUCD trades at $1.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas LUCD's P/E ratio is -1.36. In terms of profitability, XTNT's ROE is -0.27%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, XTNT is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.
XTNT vs RCEL Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, RCEL has a market cap of 166.01M. Regarding current trading prices, XTNT is priced at $0.74, while RCEL trades at $6.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas RCEL's P/E ratio is -2.87. In terms of profitability, XTNT's ROE is -0.27%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, XTNT is more volatile compared to RCEL. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs SGHT Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, SGHT has a market cap of 165.45M. Regarding current trading prices, XTNT is priced at $0.74, while SGHT trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas SGHT's P/E ratio is -3.27. In terms of profitability, XTNT's ROE is -0.27%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, XTNT is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs ELMD Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, ELMD has a market cap of 164.62M. Regarding current trading prices, XTNT is priced at $0.74, while ELMD trades at $19.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas ELMD's P/E ratio is 24.85. In terms of profitability, XTNT's ROE is -0.27%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, XTNT is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs LNSR Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, LNSR has a market cap of 161.43M. Regarding current trading prices, XTNT is priced at $0.74, while LNSR trades at $13.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas LNSR's P/E ratio is -2.79. In terms of profitability, XTNT's ROE is -0.27%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, XTNT is more volatile compared to LNSR. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs ANIK Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, ANIK has a market cap of 161.20M. Regarding current trading prices, XTNT is priced at $0.74, while ANIK trades at $11.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas ANIK's P/E ratio is -14.99. In terms of profitability, XTNT's ROE is -0.27%, compared to ANIK's ROE of -0.33%. Regarding short-term risk, XTNT is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs PROF Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, PROF has a market cap of 154.17M. Regarding current trading prices, XTNT is priced at $0.74, while PROF trades at $5.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas PROF's P/E ratio is -4.24. In terms of profitability, XTNT's ROE is -0.27%, compared to PROF's ROE of -0.70%. Regarding short-term risk, XTNT is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs BSGM Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, BSGM has a market cap of 143.84M. Regarding current trading prices, XTNT is priced at $0.74, while BSGM trades at $5.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas BSGM's P/E ratio is -9.94. In terms of profitability, XTNT's ROE is -0.27%, compared to BSGM's ROE of +7.10%. Regarding short-term risk, XTNT is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.
XTNT vs RPID Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, RPID has a market cap of 143.33M. Regarding current trading prices, XTNT is priced at $0.74, while RPID trades at $3.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas RPID's P/E ratio is -3.17. In terms of profitability, XTNT's ROE is -0.27%, compared to RPID's ROE of -0.56%. Regarding short-term risk, XTNT is more volatile compared to RPID. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs AVR Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, AVR has a market cap of 130.82M. Regarding current trading prices, XTNT is priced at $0.74, while AVR trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas AVR's P/E ratio is -1.84. In terms of profitability, XTNT's ROE is -0.27%, compared to AVR's ROE of -2.92%. Regarding short-term risk, XTNT is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.
XTNT vs LUNG Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, LUNG has a market cap of 125.20M. Regarding current trading prices, XTNT is priced at $0.74, while LUNG trades at $3.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas LUNG's P/E ratio is -2.16. In terms of profitability, XTNT's ROE is -0.27%, compared to LUNG's ROE of -0.64%. Regarding short-term risk, XTNT is more volatile compared to LUNG. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs MYO Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, MYO has a market cap of 111.35M. Regarding current trading prices, XTNT is priced at $0.74, while MYO trades at $3.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas MYO's P/E ratio is -22.11. In terms of profitability, XTNT's ROE is -0.27%, compared to MYO's ROE of -0.36%. Regarding short-term risk, XTNT is more volatile compared to MYO. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs ICAD Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, ICAD has a market cap of 102.37M. Regarding current trading prices, XTNT is priced at $0.74, while ICAD trades at $3.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas ICAD's P/E ratio is -19.63. In terms of profitability, XTNT's ROE is -0.27%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, XTNT is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs HJLI Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, HJLI has a market cap of 98.32M. Regarding current trading prices, XTNT is priced at $0.74, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas HJLI's P/E ratio is N/A. In terms of profitability, XTNT's ROE is -0.27%, compared to HJLI's ROE of -0.51%. Regarding short-term risk, XTNT is more volatile compared to HJLI. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs PTHL Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, PTHL has a market cap of 95.62M. Regarding current trading prices, XTNT is priced at $0.74, while PTHL trades at $6.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas PTHL's P/E ratio is -134.20. In terms of profitability, XTNT's ROE is -0.27%, compared to PTHL's ROE of -0.20%. Regarding short-term risk, XTNT is less volatile compared to PTHL. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.
XTNT vs ASXC Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, ASXC has a market cap of 94.92M. Regarding current trading prices, XTNT is priced at $0.74, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas ASXC's P/E ratio is -1.12. In terms of profitability, XTNT's ROE is -0.27%, compared to ASXC's ROE of -4.07%. Regarding short-term risk, XTNT is more volatile compared to ASXC. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.
XTNT vs MGRM Comparison
XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XTNT stands at 102.65M. In comparison, MGRM has a market cap of 92.79M. Regarding current trading prices, XTNT is priced at $0.74, while MGRM trades at $2.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XTNT currently has a P/E ratio of -8.19, whereas MGRM's P/E ratio is -5.20. In terms of profitability, XTNT's ROE is -0.27%, compared to MGRM's ROE of -1.26%. Regarding short-term risk, XTNT is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.